Pipeline & Platform
Pearl Therapeutics is developing fixed-dose combination product candidates for the treatment of prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma and rhinosinusitis.
Each of these product candidates incorporates approved drug actives, off-the-shelf metered dose inhaler (MDI) components, conventional manufacturing processes, and Pearl’s innovative proprietary particle platform. PT001 and PT010 are not approved by the Food and Drug Administration and are not available for commercial distribution in the United States. To learn more about our platform technology, please click here.
Glycopyrronium and formoterol (GFF MDI)
Glycopyrronium (GP MDI)
Budesonide, glycopyrronium and formoterol (BGF MDI)